Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Shoshana Gordon/Axios

The world still needs more coronavirus vaccines, particularly low-income countries. Pressure is increasing on the Biden administration to close the gap — and the Biden administration, in turn, is pushing Moderna to fill it.

Why it matters: Getting global vaccination rates as high as possible isn't just a humanitarian effort; it also reduces the risk of vaccine-resistant variants emerging.

  • But manufacturing setbacks and the prioritization of people in high-income countries have left the world facing a coronavirus vaccine deficit in the short term and inequities in the longer term.

What they're saying: "The right to make billions of dollars off of an essential medicine that was developed using government funds comes with the obligation to provide access and doses to people in low- and middle-income countries who can’t afford it," a senior Biden administration official told Axios.

  • "That is exactly what we are doing with Covax. And bilateral partnership with middle and low income countries" like Botswana and Peru, Moderna CEO Stéphane Bancel told Axios in response.
  • "And as we speak we are looking to add another [500 million] doses for mid and low income countries," he added.

One hopeful note: Vaccine manufacturing is accelerating, and worldwide production is expected to exceed 12 billion doses by the end of 2021, the International Federation of Pharmaceutical Manufacturers and Associations said yesterday.

  • "The numbers show that the scale up of vaccines is on track to ensure that everybody who needs to be vaccinated can be. We see a turning of the tide," Thomas Cueni, director general of the IFPMA, said in a statement.
  • "We will soon be at the inflection point where overall global supply of high-quality vaccines will be adequate for global needs," said Krishna Udayakumar, director of the Duke Global Health Innovation Center. "One critical issue right now is inequitable allocation of those doses."

The big picture: Nearly half of the world's population has received at least one dose of a coronavirus vaccine, per NYT.

  • But as of now, more than three-quarters of doses have been administered in high- or upper-middle-income countries.
  • It's also become clear that some vaccines work better than others, prompting concerns about low-income countries receiving less effective vaccines.

State of play: Some of the manufacturers of more effective vaccines — primarily American companies — are falling short of production expectations or selling primarily to high-income countries.

  • In March, Johnson & Johnson, Novavax and AstraZeneca were projecting they'd make a combined 6 billion doses by the end of the year. But all three have fallen short and now project a combined 2.6 billion doses, according to Udayakumar.
  • Novavax — which projected an output of 2 billion doses in 2021 — hasn't yet been approved for use anywhere in the world because of manufacturing difficulties, and J&J's production has also been curtailed by manufacturing setbacks.

These delays, combined with a ban on vaccine exports from India earlier this year, have been a blow to COVAX, the organization created to help get vaccines to lower-income countries.

  • "Those three vaccines are the ones that COVAX has been most reliant on for early access, which explains part of the supply challenges for COVAX and for low- and middle-income countries more broadly," Udayakumar said.

Meanwhile, the mRNA vaccines have emerged as the world's most effective vaccines, and activists say that the U.S. government should be more aggressive in its efforts to scale up production of these vaccines.

  • Moderna — which has received billions of dollars from the U.S. government — is facing particularly intense criticism for selling its vaccine nearly exclusively to rich countries.
  • The administration is currently in talks with the company about selling substantial quantities of doses at a not-for-profit price to go to low-income countries, which Pfizer has already agreed to do.

Between the lines: The vaccine deficit will undoubtedly grow if vaccine manufacturers continue to miss their production targets. But wealthy countries' booster efforts could also stretch supplies.

  • And the quality of vaccines matters. China has produced half of the global vaccine supply to date, but its vaccines aren't as effective as those made in the U.S. and Europe.
  • "They are quite literally better than nothing. They're just not very good by American standards or by European standards," said Cornell virologist John Moore.

Go deeper

Judge temporarily blocks Biden vaccine mandate for federal contractors

Photo: Chip Somodevilla via Getty Images

A federal judge on Tuesday temporarily blocked President Biden's vaccine mandate for federal contractors nationwide.

Why it matters: It's the latest setback in the Biden administration's rollout of COVID-19 vaccine requirements. Federal judges in two states temporarily barred the administration from enforcing mandates for millions of workers last week.

Dec 7, 2021 - Health

Report: COVID exacerbated young people's "unprecedented" mental health challenges

Surgeon General Dr. Vivek H. Murthy speaks during a press briefing in the Brady Briefing Room of the White House in Washington, D.C. on July 15. Photo: Saul Loeb/AFP via Getty Images

The U.S. surgeon general warned on Tuesday young people face "unprecedented" mental health challenges — and the pandemic has only made matters worse.

Why it matters: Depression, suicidal ideation and emergency room visits for mental health reasons have risen significantly in young people, according to the 53-page advisory from the country's top physician, Dr. Vivek H. Murthy.

Scoop: U.S. begins denying Afghan immigrants

Afghan refugees on a bus bound for temporary housing after arriving in Greece. Photo: Byron Smith/Getty Images

The Biden administration has begun issuing denials to Afghans seeking to emigrate to the United States through the humanitarian parole process, after a system that typically processes 2,000 applications annually has been flooded with more than 30,000.

Why it matters: Afghans face steeper odds and longer processes for escaping to the U.S., despite the earlier sweeping efforts by the Biden administration to assist its allies. Immigration lawyers and advocacy groups say the government has set untenable barriers to a safe haven in the U.S.